Share Price and Basic Stock Data
Last Updated: January 3, 2026, 12:17 pm
| PEG Ratio | 3.46 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Rossari Biotech Ltd operates within the specialty chemicals sector, focusing on producing a range of chemical products. The company reported total sales of ₹1,656 Cr for the fiscal year ending March 2023, which marked a substantial increase from ₹1,483 Cr in the previous year. This upward trajectory continued with sales projected to rise to ₹2,080 Cr by March 2025, reflecting a robust growth strategy. Quarterly sales figures indicate a healthy performance, with ₹483 Cr reported in September 2023, up from ₹411 Cr in June 2023. The consistent sales growth underscores Rossari’s competitive positioning within the industry, catering to diverse customer needs and expanding its market reach. However, fluctuations in quarterly performance, particularly a drop to ₹389 Cr in December 2022, highlight potential seasonality or market challenges. Overall, the revenue trend appears positive, supported by increasing demand and strategic initiatives aimed at enhancing operational capabilities.
Profitability and Efficiency Metrics
In terms of profitability, Rossari Biotech reported a net profit of ₹137 Cr for the fiscal year ending March 2025, up from ₹107 Cr in March 2023. The operating profit margin (OPM) stood at 12% for the latest reported period, which is relatively stable compared to previous years but lower than the industry average for specialty chemicals, typically around 15%. The company’s return on equity (ROE) was recorded at 12.2%, indicating efficient use of shareholder funds, while return on capital employed (ROCE) was 15.8%, reflecting effective capital utilization. The interest coverage ratio (ICR) was a strong 15.11x, suggesting that the company comfortably meets its interest obligations. However, the cash conversion cycle (CCC) of 101 days indicates potential inefficiencies in managing working capital, particularly in inventory and receivables management, which could impact liquidity and operational flexibility.
Balance Sheet Strength and Financial Ratios
Rossari Biotech’s balance sheet demonstrates a solid foundation, with total assets reported at ₹2,088 Cr as of September 2025. The company’s reserves grew significantly, reaching ₹1,240 Cr, which provides a buffer for future investments and growth initiatives. Total borrowings stood at ₹353 Cr, reflecting a manageable debt level relative to the company’s equity base, resulting in a low debt-to-equity ratio of 0.15. The current ratio was reported at 1.94, indicating adequate short-term liquidity to cover liabilities. However, the book value per share increased to ₹214.12, yet the price-to-book value (P/BV) ratio of 2.82x suggests that the stock may be trading at a premium compared to its intrinsic value. This could indicate investor confidence but also raises concerns regarding potential overvaluation if growth expectations are not met in the coming periods.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Rossari Biotech reflects a stable structure, with promoters holding 68.18% of the total shares, indicating strong control and commitment from the founding team. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), accounted for 2.70% and 18.18% of the shareholding, respectively. While FIIs have gradually decreased their stake from 8.63% in December 2022 to 2.70% by September 2025, DIIs have shown consistent support, increasing their share from 14.08% to 18.18% in the same timeframe. The public shareholding stood at 10.95%, suggesting a moderate level of retail investor participation. The overall stability in the shareholding pattern, combined with a growing number of shareholders at 91,387, demonstrates a level of investor confidence in the company’s long-term growth potential, despite the decline in foreign institutional interest.
Outlook, Risks, and Final Insight
The outlook for Rossari Biotech appears promising, supported by robust revenue growth and a solid balance sheet. However, the company faces risks, including potential fluctuations in raw material prices, which could impact margins, and the need to effectively manage working capital, as indicated by the high cash conversion cycle. Additionally, reliance on domestic markets poses risks related to economic fluctuations and regulatory changes. If the company successfully navigates these challenges while maintaining its growth trajectory, it could enhance shareholder value significantly. Conversely, failure to address operational efficiencies or external market pressures could hinder performance. Overall, investor sentiment remains cautiously optimistic, with the potential for substantial returns if strategic objectives are met and operational efficiencies are realized.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 392 Cr. | 42.7 | 80.8/40.0 | 24.4 | 20.5 | 0.94 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.2 Cr. | 63.5 | 88.8/56.0 | 14.9 | 89.6 | 1.57 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.4 Cr. | 726 | 932/600 | 22.8 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,700 Cr. | 81.6 | 111/68.2 | 24.5 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 637 Cr. | 256 | 393/230 | 22.9 | 93.8 | 0.98 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,937.80 Cr | 718.94 | 67.19 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 425 | 389 | 406 | 411 | 483 | 464 | 473 | 490 | 498 | 513 | 580 | 544 | 586 |
| Expenses | 369 | 335 | 352 | 353 | 420 | 400 | 409 | 425 | 432 | 448 | 510 | 476 | 514 |
| Operating Profit | 57 | 54 | 55 | 58 | 64 | 64 | 64 | 65 | 66 | 65 | 69 | 68 | 72 |
| OPM % | 13% | 14% | 13% | 14% | 13% | 14% | 13% | 13% | 13% | 13% | 12% | 12% | 12% |
| Other Income | 1 | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Interest | 8 | 5 | 4 | 6 | 5 | 4 | 3 | 4 | 4 | 5 | 6 | 6 | 6 |
| Depreciation | 16 | 16 | 16 | 14 | 15 | 15 | 16 | 15 | 15 | 18 | 18 | 18 | 18 |
| Profit before tax | 34 | 35 | 37 | 39 | 45 | 48 | 46 | 47 | 48 | 42 | 48 | 46 | 50 |
| Tax % | 29% | 26% | 22% | 26% | 26% | 28% | 25% | 26% | 27% | 25% | 28% | 27% | 26% |
| Net Profit | 24 | 26 | 29 | 29 | 33 | 34 | 34 | 35 | 35 | 32 | 34 | 34 | 37 |
| EPS in Rs | 4.34 | 4.66 | 5.25 | 5.30 | 5.97 | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 |
Last Updated: December 29, 2025, 8:02 am
Below is a detailed analysis of the quarterly data for Rossari Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 586.00 Cr.. The value appears strong and on an upward trend. It has increased from 544.00 Cr. (Jun 2025) to 586.00 Cr., marking an increase of 42.00 Cr..
- For Expenses, as of Sep 2025, the value is 514.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 476.00 Cr. (Jun 2025) to 514.00 Cr., marking an increase of 38.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 72.00 Cr.. The value appears strong and on an upward trend. It has increased from 68.00 Cr. (Jun 2025) to 72.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 12.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Depreciation, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 18.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 4.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Jun 2025) to 26.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Jun 2025) to 37.00 Cr., marking an increase of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 6.66. The value appears strong and on an upward trend. It has increased from 6.07 (Jun 2025) to 6.66, marking an increase of 0.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:43 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,222 |
| Expenses | 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 1,948 |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 274 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% |
| Other Income | 1 | 4 | 9 | 13 | 6 | 8 | 5 | 7 |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 22 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 73 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 186 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | |
| Net Profit | 46 | 65 | 80 | 98 | 107 | 131 | 136 | 137 |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 24.68 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 41.30% | 23.08% | 22.50% | 9.18% | 22.43% | 3.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.23% | -0.58% | -13.32% | 13.25% | -18.61% |
Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -14% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: December 4, 2025, 1:53 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,240 |
| Borrowings | 8 | 67 | 0 | 8 | 74 | 119 | 218 | 353 |
| Other Liabilities | 118 | 118 | 152 | 442 | 375 | 401 | 482 | 484 |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
| Fixed Assets | 74 | 94 | 181 | 607 | 585 | 578 | 598 | 630 |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 247 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 20 |
| Other Assets | 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,190 |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
Below is a detailed analysis of the balance sheet data for Rossari Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,240.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,174.00 Cr. (Mar 2025) to 1,240.00 Cr., marking an increase of 66.00 Cr..
- For Borrowings, as of Sep 2025, the value is 353.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 218.00 Cr. (Mar 2025) to 353.00 Cr., marking an increase of 135.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 484.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 482.00 Cr. (Mar 2025) to 484.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,088.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 630.00 Cr.. The value appears strong and on an upward trend. It has increased from 598.00 Cr. (Mar 2025) to 630.00 Cr., marking an increase of 32.00 Cr..
- For CWIP, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 140.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 107.00 Cr..
- For Investments, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 64.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,190.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,063.00 Cr. (Mar 2025) to 1,190.00 Cr., marking an increase of 127.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,088.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (1,240.00 Cr.) exceed the Borrowings (353.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 70.00 | 38.00 | 124.00 | 176.00 | 149.00 | 131.00 | 47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Small Cap Fund | 2,016,342 | 0.33 | 121.01 | 2,016,798 | 2025-12-08 04:48:22 | -0.02% |
| UTI Flexi Cap Fund | 1,700,000 | 0.4 | 102.03 | 1,747,000 | 2025-12-15 01:39:12 | -2.69% |
| Canara Robeco Small Cap Fund | 1,067,293 | 0.49 | 64.05 | 1,067,293 | 2025-04-22 15:56:53 | 0% |
| UTI Small Cap Fund | 597,345 | 0.74 | 35.85 | 407,215 | 2025-12-08 01:35:25 | 46.69% |
| UTI Large & Mid Cap Fund | 384,468 | 0.42 | 23.07 | N/A | N/A | N/A |
| UTI Aggressive Hybrid Fund | 361,969 | 0.32 | 21.72 | N/A | N/A | N/A |
| UTI Retirement Fund | 142,863 | 0.18 | 8.57 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 24.66 | 23.67 | 19.46 | 17.81 | 15.56 |
| Diluted EPS (Rs.) | 24.63 | 23.62 | 19.38 | 17.70 | 15.47 |
| Cash EPS (Rs.) | 36.57 | 34.56 | 30.68 | 26.19 | 19.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Revenue From Operations / Share (Rs.) | 375.74 | 331.35 | 300.22 | 269.36 | 136.60 |
| PBDIT / Share (Rs.) | 48.60 | 46.56 | 41.43 | 35.50 | 25.47 |
| PBIT / Share (Rs.) | 36.49 | 35.63 | 30.02 | 26.77 | 21.07 |
| PBT / Share (Rs.) | 33.27 | 32.12 | 25.97 | 24.47 | 20.49 |
| Net Profit / Share (Rs.) | 24.46 | 23.62 | 19.27 | 17.46 | 15.34 |
| NP After MI And SOA / Share (Rs.) | 24.63 | 23.66 | 19.45 | 17.74 | 15.45 |
| PBDIT Margin (%) | 12.93 | 14.05 | 13.79 | 13.17 | 18.64 |
| PBIT Margin (%) | 9.71 | 10.75 | 9.99 | 9.93 | 15.42 |
| PBT Margin (%) | 8.85 | 9.69 | 8.65 | 9.08 | 15.00 |
| Net Profit Margin (%) | 6.50 | 7.12 | 6.41 | 6.48 | 11.22 |
| NP After MI And SOA Margin (%) | 6.55 | 7.13 | 6.47 | 6.58 | 11.30 |
| Return on Networth / Equity (%) | 11.50 | 12.47 | 11.71 | 12.13 | 19.62 |
| Return on Capital Employeed (%) | 14.85 | 17.15 | 16.22 | 15.31 | 26.61 |
| Return On Assets (%) | 7.19 | 8.31 | 7.84 | 7.77 | 14.29 |
| Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.03 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.15 | 0.10 | 0.08 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 1.20 | 1.25 | 1.26 | 1.63 | 1.37 |
| Current Ratio (X) | 1.94 | 1.99 | 2.08 | 2.07 | 2.36 |
| Quick Ratio (X) | 1.28 | 1.32 | 1.54 | 1.42 | 1.73 |
| Inventory Turnover Ratio (X) | 6.53 | 5.22 | 5.70 | 6.80 | 5.66 |
| Dividend Payout Ratio (NP) (%) | 2.02 | 2.11 | 2.56 | 2.81 | 3.16 |
| Dividend Payout Ratio (CP) (%) | 1.35 | 1.44 | 1.61 | 1.88 | 2.46 |
| Earning Retention Ratio (%) | 97.98 | 97.89 | 97.44 | 97.19 | 96.84 |
| Cash Earning Retention Ratio (%) | 98.65 | 98.56 | 98.39 | 98.12 | 97.54 |
| Interest Coverage Ratio (X) | 15.11 | 13.28 | 10.24 | 15.44 | 44.20 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 7.74 | 5.76 | 8.60 | 27.62 |
| Enterprise Value (Cr.) | 3475.13 | 3801.34 | 3233.01 | 4985.62 | 5300.00 |
| EV / Net Operating Revenue (X) | 1.67 | 2.08 | 1.95 | 3.36 | 7.47 |
| EV / EBITDA (X) | 12.91 | 14.78 | 14.15 | 25.51 | 40.08 |
| MarketCap / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| Retention Ratios (%) | 97.97 | 97.88 | 97.43 | 97.18 | 96.83 |
| Price / BV (X) | 2.82 | 3.56 | 3.59 | 6.25 | 13.18 |
| Price / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| EarningsYield | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Rossari Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.67 (Mar 24) to 24.66, marking an increase of 0.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.63, marking an increase of 1.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 36.57. This value is within the healthy range. It has increased from 34.56 (Mar 24) to 36.57, marking an increase of 2.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 375.74. It has increased from 331.35 (Mar 24) to 375.74, marking an increase of 44.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.60. This value is within the healthy range. It has increased from 46.56 (Mar 24) to 48.60, marking an increase of 2.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 36.49. This value is within the healthy range. It has increased from 35.63 (Mar 24) to 36.49, marking an increase of 0.86.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.27. This value is within the healthy range. It has increased from 32.12 (Mar 24) to 33.27, marking an increase of 1.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.46. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.46, marking an increase of 0.84.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.66 (Mar 24) to 24.63, marking an increase of 0.97.
- For PBDIT Margin (%), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 14.05 (Mar 24) to 12.93, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 9.71. This value is below the healthy minimum of 10. It has decreased from 10.75 (Mar 24) to 9.71, marking a decrease of 1.04.
- For PBT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has decreased from 9.69 (Mar 24) to 8.85, marking a decrease of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 7.12 (Mar 24) to 6.50, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.55. This value is below the healthy minimum of 8. It has decreased from 7.13 (Mar 24) to 6.55, marking a decrease of 0.58.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 15. It has decreased from 12.47 (Mar 24) to 11.50, marking a decrease of 0.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has decreased from 17.15 (Mar 24) to 14.85, marking a decrease of 2.30.
- For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 8.31 (Mar 24) to 7.19, marking a decrease of 1.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.20. It has decreased from 1.25 (Mar 24) to 1.20, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.94, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.28, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.53. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 6.53, marking an increase of 1.31.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 20. It has decreased from 2.11 (Mar 24) to 2.02, marking a decrease of 0.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 20. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Mar 25, the value is 97.98. This value exceeds the healthy maximum of 70. It has increased from 97.89 (Mar 24) to 97.98, marking an increase of 0.09.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.65. This value exceeds the healthy maximum of 70. It has increased from 98.56 (Mar 24) to 98.65, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.11. This value is within the healthy range. It has increased from 13.28 (Mar 24) to 15.11, marking an increase of 1.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 8.60, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,475.13. It has decreased from 3,801.34 (Mar 24) to 3,475.13, marking a decrease of 326.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.67, marking a decrease of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 12.91. This value is within the healthy range. It has decreased from 14.78 (Mar 24) to 12.91, marking a decrease of 1.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For Retention Ratios (%), as of Mar 25, the value is 97.97. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 97.97, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 2.82. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.82, marking a decrease of 0.74.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
- Net Profit Margin: 6.5%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.85% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.5% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.6 (Industry average Stock P/E: 67.19)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.15
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.5%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Rossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Edward Menezes | Executive Chairman |
| Mr. Sunil Chari | Managing Director |
| Mr. Aseem Dhru | Independent Director |
| Ms. Aparna Sharma | Independent Director |
| Ms. Esha Achan | Independent Director |
| Mr. Gurudas Aras | Independent Director |
FAQ
What is the intrinsic value of Rossari Biotech Ltd?
Rossari Biotech Ltd's intrinsic value (as of 04 January 2026) is ₹521.03 which is 10.78% lower the current market price of ₹584.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,232 Cr. market cap, FY2025-2026 high/low of ₹841/562, reserves of ₹1,240 Cr, and liabilities of ₹2,088 Cr.
What is the Market Cap of Rossari Biotech Ltd?
The Market Cap of Rossari Biotech Ltd is 3,232 Cr..
What is the current Stock Price of Rossari Biotech Ltd as on 04 January 2026?
The current stock price of Rossari Biotech Ltd as on 04 January 2026 is ₹584.
What is the High / Low of Rossari Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Rossari Biotech Ltd stocks is ₹841/562.
What is the Stock P/E of Rossari Biotech Ltd?
The Stock P/E of Rossari Biotech Ltd is 23.6.
What is the Book Value of Rossari Biotech Ltd?
The Book Value of Rossari Biotech Ltd is 226.
What is the Dividend Yield of Rossari Biotech Ltd?
The Dividend Yield of Rossari Biotech Ltd is 0.09 %.
What is the ROCE of Rossari Biotech Ltd?
The ROCE of Rossari Biotech Ltd is 15.8 %.
What is the ROE of Rossari Biotech Ltd?
The ROE of Rossari Biotech Ltd is 12.2 %.
What is the Face Value of Rossari Biotech Ltd?
The Face Value of Rossari Biotech Ltd is 2.00.